Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
287.70
+1.21 (0.42%)
At close: Jan 16, 2026, 4:00 PM EST
289.00
+1.30 (0.45%)
After-hours: Jan 16, 2026, 5:31 PM EST
Insulet Revenue
Insulet had revenue of $706.30M in the quarter ending September 30, 2025, with 29.86% growth. This brings the company's revenue in the last twelve months to $2.01B, up 1.33% year-over-year. In the year 2024, Insulet had annual revenue of $2.07B with 22.07% growth.
Revenue (ttm)
$2.01B
Revenue Growth
+1.33%
P/S Ratio
8.02
Revenue / Employee
$646,615
Employees
3,900
Market Cap
20.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.07B | 374.50M | 22.07% |
| Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
| Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
| Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
| Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
| Dec 31, 2019 | 738.20M | 174.40M | 30.93% |
| Dec 31, 2018 | 563.80M | 100.00M | 21.56% |
| Dec 31, 2017 | 463.80M | 96.81M | 26.38% |
| Dec 31, 2016 | 366.99M | 103.10M | 39.07% |
| Dec 31, 2015 | 263.89M | 32.57M | 14.08% |
| Dec 31, 2014 | 231.32M | -15.76M | -6.38% |
| Dec 31, 2013 | 247.08M | 35.72M | 16.90% |
| Dec 31, 2012 | 211.37M | 59.11M | 38.83% |
| Dec 31, 2011 | 152.26M | 55.29M | 57.02% |
| Dec 31, 2010 | 96.97M | 30.93M | 46.85% |
| Dec 31, 2009 | 66.03M | 29.97M | 83.12% |
| Dec 31, 2008 | 36.06M | 22.69M | 169.66% |
| Dec 31, 2007 | 13.37M | 9.71M | 265.06% |
| Dec 31, 2006 | 3.66M | 3.61M | 7,226.00% |
| Dec 31, 2005 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PODD News
- 4 days ago - Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 8 days ago - Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 - Business Wire
- 11 days ago - Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health - Business Wire
- 4 weeks ago - Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future - Business Wire
- 5 weeks ago - Eight stock picks to play one of the healthiest corners of the market - Market Watch
- 6 weeks ago - Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience - Business Wire
- 7 weeks ago - Artisan International Small-Mid Fund Q3 2025 Contrarianism Pays Off - Seeking Alpha